This study is not yet accepting patients
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 2-17 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jeannie Huang
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UCSD
- Jeannie Huang
Professor In Residence, Pediatrics, Vc-health Sciences-schools. Authored (or co-authored) 82 research publications
Details
- Status
- not yet accepting patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease (AMAY)
- ID
- NCT05509777
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 90 study participants
- Last Updated